{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:49:57Z","timestamp":1780336197910,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1UL1TR001425-01"],"award-info":[{"award-number":["1UL1TR001425-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.bbmt.2016.09.016","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T19:30:31Z","timestamp":1474486231000},"page":"2220-2225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"22","author":[{"given":"Pooja","family":"Khandelwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Neumeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Dandoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"El-Bietar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharat","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Bleesing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinda A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonata","family":"Jodele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Grimley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasiani C.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.09.016_bib0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.beha.2008.02.011","article-title":"Impact of graft-versus-host disease on survival","volume":"21","author":"Pasquini","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0015","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","article-title":"How I treat refractory aGVHD","volume":"109","author":"Deeg","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2003-12-4241","article-title":"Tumor necrosis factor-alpha blockade for the treatment of aGVHD","volume":"104","author":"Couriel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0025","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bmt.1705306","article-title":"Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist","volume":"37","author":"Funke","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0030","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2004-01-0028","article-title":"Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Ho","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0035","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.bbmt.2005.05.009","article-title":"Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease","volume":"11","author":"Uberti","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0040","author":"Bayer Health Pharmaceuticals U"},{"issue":"2","key":"10.1016\/j.bbmt.2016.09.016_bib0045","article-title":"Alemtuzumab for patients with chronic lymphocytic leukaemia","author":"Skoetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0050","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10875-011-9533-7","article-title":"Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis","volume":"31","author":"Reiff","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0060","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.bbmt.2015.04.009","volume":"21","author":"Marsh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact aGVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0070","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","article-title":"In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation","volume":"96","author":"Kottaridis","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.bmt.1704573","article-title":"Successful use of Campath-1H in the treatment of steroid refractory liver GvHD","volume":"34","author":"Wandroo","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0080","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.bbmt.2014.05.031","article-title":"Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease","volume":"20","author":"Meunier","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2009.01.014","article-title":"Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study","volume":"15","author":"Martinez","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbmt.2007.08.052","article-title":"Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease","volume":"14","author":"Gomez-Almaguer","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.bmt.1704322","article-title":"Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD)","volume":"33","author":"Carella","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0100","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbmt.2005.05.010","article-title":"Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H","volume":"11","author":"Busca","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0105","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bbmt.2009.04.002","article-title":"Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab","volume":"15","author":"Schnitzler","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0110","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/bmt.2016.83","article-title":"Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory aGVHD","volume":"51","author":"Tey","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0115","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbmt.2013.02.009","article-title":"Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease","volume":"19","author":"Nikiforow","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/petr.12183","article-title":"The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients","volume":"18","author":"Khandelwal","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0125","first-page":"825","article-title":"1994 consensus conference on AGVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0130","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-1759(01)00556-7","article-title":"Pharmacokinetics of CAMPATH-1H: assay development and validation","volume":"260","author":"Rebello","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0135","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1705761","article-title":"Infliximab for GVHD therapy in children","volume":"40","author":"Sleight","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0140","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.bmt.1703737","article-title":"Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation","volume":"30","author":"Massenkeil","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/bmt.2008.331","article-title":"Daclizumab as useful treatment in refractory aGVHD: a paediatric experience","volume":"43","author":"Miano","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/bmt.2010.68","article-title":"Therapy of steroid-refractory aGVHD with CD52 antibody alemtuzumab is effective","volume":"46","author":"Schub","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0155","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/(SICI)1096-8652(199607)52:3<236::AID-AJH23>3.0.CO;2-C","article-title":"In vivo CAMPATH-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease","volume":"52","author":"Varadi","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.09.016_bib0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116303561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116303561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:56:35Z","timestamp":1761058595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116303561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1083879116303561"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}